Tags

Type your tag names separated by a space and hit enter

Hydroxyurea therapy in thalassemia.
Ann N Y Acad Sci 1998; 850:120-8AN

Abstract

The clinical effectiveness of Hydroxyurea in thalassemia is still controversial. The present paper puts together the authors' experience in two groups of patients with thalassemia intermedia and sickle cell/beta-thalassemia treated with varying dosages of hydroxyurea over several months. A third group received hydroxyurea along with recombinant human erythropoietin. Our observations are summarized in that treatment with hydroxyrea results in a significant increase of fetal hemoglobin with no change of the total hemoglobin levels. The drug causes also a considerable increase of the erythrocyte volume and hemoglobin content while the MCHC values remain unchanged. As a rule, and without objective criteria so far, patients state feeling better and having more energy. The authors postulate that this feeling may reflect the significant decrease of ineffective erythropoiesis resulting by the replacement of the poorly hemoglobinized, prematurely dying erythroid progenitor and red cell population by another population of cells with higher hemoglobin content and longer survival, the regeneration of which requires less energy and consumption. As expected, patients with sickle cell/beta-thalassemia have also fewer crises and painful episodes. The above findings are in keeping with the few available reports in the literature.

Authors+Show Affiliations

First Department of Medicine, University of Athens, Laikon Hospital, Greece. dloukop@atlas.uoa.grNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9668534

Citation

Loukopoulos, D, et al. "Hydroxyurea Therapy in Thalassemia." Annals of the New York Academy of Sciences, vol. 850, 1998, pp. 120-8.
Loukopoulos D, Voskaridou E, Stamoulakatou A, et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci. 1998;850:120-8.
Loukopoulos, D., Voskaridou, E., Stamoulakatou, A., Papassotiriou, Y., Kalotychou, V., Loutradi, A., ... Pavlides, N. (1998). Hydroxyurea therapy in thalassemia. Annals of the New York Academy of Sciences, 850, pp. 120-8.
Loukopoulos D, et al. Hydroxyurea Therapy in Thalassemia. Ann N Y Acad Sci. 1998 Jun 30;850:120-8. PubMed PMID: 9668534.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hydroxyurea therapy in thalassemia. AU - Loukopoulos,D, AU - Voskaridou,E, AU - Stamoulakatou,A, AU - Papassotiriou,Y, AU - Kalotychou,V, AU - Loutradi,A, AU - Cozma,G, AU - Tsiarta,H, AU - Pavlides,N, PY - 1998/7/21/pubmed PY - 1998/7/21/medline PY - 1998/7/21/entrez SP - 120 EP - 8 JF - Annals of the New York Academy of Sciences JO - Ann. N. Y. Acad. Sci. VL - 850 N2 - The clinical effectiveness of Hydroxyurea in thalassemia is still controversial. The present paper puts together the authors' experience in two groups of patients with thalassemia intermedia and sickle cell/beta-thalassemia treated with varying dosages of hydroxyurea over several months. A third group received hydroxyurea along with recombinant human erythropoietin. Our observations are summarized in that treatment with hydroxyrea results in a significant increase of fetal hemoglobin with no change of the total hemoglobin levels. The drug causes also a considerable increase of the erythrocyte volume and hemoglobin content while the MCHC values remain unchanged. As a rule, and without objective criteria so far, patients state feeling better and having more energy. The authors postulate that this feeling may reflect the significant decrease of ineffective erythropoiesis resulting by the replacement of the poorly hemoglobinized, prematurely dying erythroid progenitor and red cell population by another population of cells with higher hemoglobin content and longer survival, the regeneration of which requires less energy and consumption. As expected, patients with sickle cell/beta-thalassemia have also fewer crises and painful episodes. The above findings are in keeping with the few available reports in the literature. SN - 0077-8923 UR - https://www.unboundmedicine.com/medline/citation/9668534/Hydroxyurea_therapy_in_thalassemia_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=1998&volume=850&spage=120 DB - PRIME DP - Unbound Medicine ER -